AQS TSX-V
Data as of
Minimum 20 minute delay
AQSZF OTCQB
Data as of
Minimum 20 minute delay

Overview

We are a rapidly growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus’ sales and marketing efforts are based in Canada, targeting highly specialized therapeutic areas including neurology, ophthalmology and transplant.

Aequus is developing a pipeline of products in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada and to establish strategic partnerships to accelerate and maximize the potential of its product candidates worldwide.

products & pipeline

  • Marketed
  • Pre-Registration
  • Development
Commercialized

Zepto® Capsulotomy

Cataract
Precision Pulse System

Zepto® provides consistent, high quality anterior lens capsulotomies during cataract surgery in a convenient, cost-effective, disposable format. Zepto® integrates seamlessly into the routine steps of cataract surgery with phacoemulsification. Zepto® has been used in thousands of cataract surgeries in Asia, Europe, and Central America since February 2017, and most recently in the US since August 2017.

Status

Currently marketed in Canada

Launched

Zepto® Capsulotomy

Cataractes
Système à impulsions précises

Le produit Zepto fournit des capsulotomies uniformes et de haute qualité de la capsule antérieure du cristallin pendant la chirurgie de la cataracte, et se présente sous un format pratique, économique et jetable. Zepto s’intègre harmonieusement dans les étapes courantes de la chirurgie de la cataracte avec phacoémulsification. Zepto a été utilisé au cours de milliers de chirurgies de la cataracte en Asie, en Europe et en Amérique centrale depuis février 2017, et plus récemment aux États-Unis, depuis 2017.

Status

Actuellement commercialisé au Canada

Lancé

PrVistitanTM

Glaucoma
Bimatoprost 0.03%, ophthalmic solution

Bimatoprost 0.03% is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension. PrVistitanTMis currently the only marketed version of 0.03% bimatoprost ophthalmic solution for this indication in Canada and demonstrates that best ratio of safety to efficacy for this strength of the molecule. Aequus began Canadian promotional activities on behalf of its partner, for PrVistitanTMin May 2016.

Status

Currently marketed in Canada

Launched

PrVistitanTM

Glaucome
Bimatoprost 0,03%, solution ophtalmique

Le bimatoprost 0,03 % est une prostaglandine approuvée pour la réduction de la pression intraoculaire élevée chez les patients atteints d’un glaucome à angle ouvert ou d’une hypertension oculaire. À l’heure actuelle, PrVistitanMC est la seule version de la solution ophtalmique de bimatoprost 0,03 % mise en marché pour cette indication au Canada et présente le meilleur rapport efficacité/innocuité pour cette puissance de molécule. Aequus a entrepris ses activités promotionnelles au Canada visant PrVistitanMC en mai 2016, au nom de son partenaire.

Status

Actuellement commercialisé au Canada

Lancé

Tacrolimus IR

Transplant
Immediate-release oral tablet

Aequus began promotional activities on Tacrolimus IR in December 2015. It was and remains the only lower cost alternative to the brand Prograf® currently marketed in Canada. Tacrolimus IR is indicated for the treatment and prevention of acute rejection following solid organ transplantation (liver, kidney and heart). Tacrolimus is part of a patient’s immunosuppressive therapy prescribed chronically in their lifelong management to prevent graft rejection.

Status

Currently marketed in Canada

Launched

Tacrolimus IR

Transplantation
Comprimé oral à libération immediate

Aequus a entrepris ses activités promotionnelles visant le produit Tacrolimus IR en décembre 2015. Ce produit était, et reste toujours, la seule solution de rechange la moins coûteuse à la marquePrografMD, actuellement commercialisée au Canada. Tacrolimus IR est indiqué pour le traitement et la prévention d’un rejet aigu découlant de la transplantation d’un organe plein (foie, rein et cœur). Dans le cadre de la thérapie immunosuppressive du patient et de la gestion à vie de son état le tacrolimus est prescrit de façon chronique pour prévenir le rejet de la greffe.

Status

Actuellement commercialisé au Canada

Lancé
  • Neurology
  • Ophthalmology
  • Transplant
  • Women's Health
Pre-Registration

Topiramate XR

Epilepsy
Extended-release topiramate oral tablet

A once-daily topiramate product designed to improve patient compliance and to show an equivalent pharmacokinetic profile than the currently available immediate release products, which is dosed twice-daily. Aequus in-licensed Canadian commercial rights to Topiramate XR from Supernus Pharmaceuticals and is currently preparing an application to Health Canada seeking approval. Topiramate immediate release is currently approved in Canada for use in epilepsy and prophylactic migraine.

Status

Pre-registration in Canada

Pre-Registration

Topiramate XR

Épilepsie
Comprimé oral à libération prolongée

Le produit Topiramate XR à dose unique quotidienne est conçu pour améliorer l’observance du patient et présenter un profil pharmacocinétique équivalant à celui des produits à libération immédiate actuellement sur le marché, qui sont pris deux fois par jour. Aequus a convenu un accord avec Supernus Pharmaceuticals pour les droits de commercialisation au Canada du produit Topiramate XR et prépare une demande d’approbation auprès de Santé Canada. Le topiramate à libération immédiate est déjà approuvé au Canada pour le traitement de l’épilepsie ainsi que le traitement prophylactique de la migraine.

Status

Pré-inscription au Canada

Pré-enregistrement

Oxcarbazepine XR

Epilepsy
Extended-release oxcarbazepine oral tablet

A once-daily oxcarbazepine product designed to improve patient compliance with a novel pharmacokinetic profile and more consistent blood levels compared to immediate release products. Aequus in-licensed Canadian commercial rights to Oxcarbazepine XR from Supernus Pharmaceuticals and is currently preparing an application to Health Canada seeking approval. Oxcarbazepine immediate release is currently approved in Canada for use in partial seizures in epilepsy.

Status

Pre-registration in Canada

Pre-Registration

Oxcarbazepine XR

Épilepsie
Comprimé oral à libération prolongée

Le produit Oxcarbazépine XR à dose unique quotidienne est conçu pour améliorer l’observance du patient à l’aide d’un nouveau profil pharmacocinétique et procurer des concentrations sanguines du médicament plus constantes que celles des produits à libération immédiate. Aequus a convenu un accord avec Supernus Pharmaceuticals pour les droits de commercialisation au Canada du produit Oxcarbazepine XR et prépare actuellement une demande d’approbation auprès de Santé Canada. L’oscarbazépine à libération immédiate est déjà approuvé au Canada pour le traitement des crises partielles d’épilepsie.

Status

Pré-inscription au Canada

Pré-enregistrement
In Development

AQS1301

Psychiatric Disorders
Transdermal aripiprazole

Aripiprazole is an atypical anti-psychotic sold under the brand name Abilify® and is approved for many neurological conditions including schizophrenia, bipolar I, and major depressive disorder. A long-acting transdermal form of aripiprazole is being developed by Aequus to deliver aripiprazole at levels comparable to currently marketed once-daily formulations with the intention of improving patient compliance and providing better outcomes. Aequus has completed two-proof of concept studies for this potential product to date, and intends to pursue a 505(b)2 pathway for regulatory approval in the United States.

Status

Global rights available

Clinical

AQS1301

Troubles psychiatriques
Aripiprazole transdermique

L’aripiprazole est un antipsychotique atypique vendu sous la marque AbilifyMD et est approuvé pour le traitement de nombreux troubles neurologiques tels que la schizophrénie, le trouble bipolaire de type 1 et le trouble dépressif majeur. Aequus est en voie de développer une forme transdermique à action prolongée qui permettra d’administrer l’aripiprazole à des niveaux comparables à ceux des formulations à dose unique quotidienne actuellement sur le marché, et ce, afin d’améliorer à la fois l’observance des patients et les résultats chez ces derniers. À ce jour, Aequus a effectué deux études de validation et a tenu une séance pré-DNR avec la FDA au sujet de ce produit potentiel, et prévoit s’engager dans le processus 505(b)(2) afin d’obtenir l’approbation réglementaire aux États-Unis.

Status

Droits globaux disponibles

Clinique

AQS1303

anti-nausea
Transdermal pyridoxine / doxylamine

Pyridoxine/doxylamine is currently marketed as Diclegis® (United States)/Diclectin® (Canada) for the treatment of Nausea and Vomiting of Pregnancy. It is taken orally, dosed up to four times per day. A long-acting transdermal form of pyridoxine/doxylamine is being developed by Aequus to address the risk of missed doses due to emesis (vomiting), provide consistent symptomatic relief, ease pill burden, and improve compliance. Aequus is preparing for its first Proof of Concept study for this product, and intends to pursue a 505(b)2 pathway for regulatory approval in the United States.

Status

Global rights available

Clinical

AQS1303

Anti-nauséeux
Pyridoxine/doxylamine transdermique

La pyridoxine/doxylamine est actuellement commercialisée sous le nom Diclegis® (États-Unis)/DiclectinMD (Canada) pour le traitement de la nausée et des vomissements lors de la grossesse. Ce médicament, sous forme orale, peut être pris jusqu’à quatre fois par jour. Aequus est en voie de développer une forme transdermique à action prolongée de la pyridoxine/doxylamine afin de réduire le risque d’omission de doses en raison de vomissements, de procurer un soulagement symptomatique constant, de réduire le fardeau associé à la posologie et d’améliorer l’observance. Aequus a effectué une étude initiale de validation et prévoit s’engager dans le processus 505(b)(2) afin d’obtenir l’approbation réglementaire aux États-Unis.

Status

Droits globaux disponibles

Clinique

AQS1304

neurological disorders
Transdermal medical cannabis

Medical cannabis is lacking in three main categories - dose delivery, dose consistency, and clinical data support. Aequus’ cannabinoid program is being developed to directly address these barriers. Throughout development Aequus will be working closely with patients and physicians with the goal to provide a cannabinoid product that is safe, consistent, targeted, and effective.

Status

Global rights available

Pre-Clinical

AQS1304

Troubles neurologiques
Cannabis thérapeutique transdermique

Le cannabis thérapeutique comporte des lacunes dans trois principales catégories : administration des doses, constance des doses et données cliniques à l’appui. Aequus se penche sur l’élaboration d’un programme de timbres transdermiques à cannabinoïde pour éliminer directement ces obstacles. Tout au long du processus, Aequus travaillera en étroite collaboration avec des patients et des médecins en vue de produire un cannabinoïde sûr, uniforme, ciblé et efficace.

Status

Droits globaux disponibles

Pré-clinique
  • Neurology
  • Ophthalmology
  • Transplant
  • Women's Health

Zepto® Achieve

precise, visually centered, and stronger
capsulotomies in the blink of an eye

Our Team

Doug Janzen

Chairman & CEO

Doug Janzen
Chairman & Chief Executive Officer

Doug Janzen has been involved in the Life Sciences industry for the past 19 years. He is currently the Founder and President of Northview Ventures, an organization which invests in and provides strategic advisory services to a number of technology companies. Mr Janzen was part of the founding group of Aequus Pharmaceuticals. Previously, Mr Janzen was President and CEO of Cardiome Pharma, a NASDAQ listed drug development company that raised over $300 million from investors, and completed over $1 billion in licensing deals during his tenure. In 2010, Cardiome’s lead product, Brinavess, was approved and launched in Europe by Merck. Prior to that, he was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. Mr Janzen is Past Chair of LifeSciences BC, has served as a Director with Biotech Canada and currently sits as a Director on a number of public and private boards. He is a past winner of Business in Vancouver’s Top 40 Under 40 Award.

Anne Stevens MHA

COO & Director

Anne Stevens MHA
Chief Operating Officer & Director

Ms Stevens has over ten years of progressive experience in the Pharmaceutical, Biotech, and Medical Device industry. Anne is the Co-Founder and Senior Partner of Northview Ventures, an entity which invests in and provides strategic advisory services to a number of life sciences companies. Ms Stevens was part of the founding group of Aequus Pharmaceuticals and previously held the title of VP of Corporate Development. Prior to her involvement with Aequus, Ms Stevens served as the Corporate and External Affairs Analyst for Cardiome Pharma, where she was responsible for strategic planning and value analysis of internal R&D. Ms Stevens’ earlier experience includes 5 years with Bayer HealthCare, where she was responsible for the commercial success and business development of a portfolio of products within several key therapeutic areas.

Donald McAfee PhD

CSO

Donald McAfee PhD
Chief Scientific Officer

Dr. McAfee has been a scientist and manager in academia and industry for more than 40 years. Most recently, he was Cardiome Pharma’s Chief Scientific Officer after serving as Vice President of New Product Development since 2004. Previously, he was Founder, Chief Executive Officer, and Chief Technical Officer of Aderis Pharmaceuticals, Inc. where he led the introduction of a number of clinical candidates including a therapeutic patch for Parkinson’s disease, now marketed.

Ian Ball

CCO

Ian Ball
Chief Commercial Officer

Ian joined the Pharma industry in 1995 and has spent the last 20 years in various sales and marketing roles for multinational companies. His experience is unique; an experienced General Manager across multiple territories, a top rated medical representative, award winning marketer, recognized expert in commercial supply chain within Pharma and an industry leader in parallel trade management. Ian has led Board level initiatives in Novartis and consulted with other Pharma companies on portfolio management and commercial strategy.

Ian’s most recent role was as CEO of TeOra Health, a specialty pharma company with a focus on Ophthalmology and Transplant which was acquired by Aequus Pharmaceuticals Inc. 

Ann Fehr CPA • CGA

CFO

Ann Fehr CPA • CGA
Chief Financial Officer

Ms. Fehr is the Principal at Fehr & Associates, and has held a number of senior level positions including having served as CFO of Carrus Capital Corporation (formerly BioWest Therapeutic Inc.), Global Minerals Ltd., and other companies listed on the TSX. During the course of her management and consulting career, Ms. Fehr has led a number of companies through significant change and corporate milestones such as public listing applications, mergers and acquisitions, as well as strategic planning and execution. Ms. Fehr is also an active volunteer in the community. Since 2013, she has been Treasurer and a Director for the Boys and Girls Clubs of South Coast BC.

James Purdy MBA

Director of Operations

James Purdy MBA
Director of Operations

James has been with Aequus from the beginning, managing a wide range of key functional areas within the company that include finance, market research, deal diligence, and sales operations. In addition, James currently works as an Associate with Northview Ventures, a life science focused investment and consulting firm that works to commercialize innovative technologies. In this role, James works closely with academic researchers to help transform their research in the lab into a successful commercial entity. Prior to joining Aequus, James worked in sales as an account manager with Life Technologies (acquired by Thermo Fisher). Handling a research and diagnostics portfolio in genetic sequencing, qPCR, and Cell Analysis, James was recognized as the Top Account Executive in North America. James currently holds a BSc in Molecular Biology from McMaster University and an MBA from the Sauder School of Business at UBC.

Chris Clark PgD • CA

Director

Chris Clark PgD • CA
Director

Mr. Clark has over 20 years finance and accounting experience in public practice and in public and private companies, most recently focused in the medical device sector. Previous experience includes financial leadership roles with large automotive and telecom firms in which he developed deep expertise in the development and management of sophisticated financial systems. A highly sought after consultant for biotechnology startups, Mr. Clark accepted the role of Chief Financial Officer at Neovasc Inc. and was instrumental in the initial and ongoing development of Neovasc as a publicly traded company. He received his designation as a Chartered Accountant from the Institute of Chartered Accountants of England and Wales and articled with KPMG before moving to Canada from England in 1998. He has an honors degree in Economics from Swansea University and a post graduate diploma from Keble College, Oxford.

Damien King MBA

Director

Damien King MBA
Director

With over 20 years in the pharmaceutical industry, Damien is a proven executive leader, with a track record of consistent sales growth and an ability to effectively manage operations through clear strategic direction, all while creating positive, corporate cultures. Currently Director of Sales with Merz Pharma Canada, he sits as a founding member of their Senior Leadership Team, and over the past 9 years has worked hard to transform the company from a single brand entity, to an integrated product portfolio organization with 5 divisions and multiple high performing teams. He has been presented with numerous awards throughout his career, recognizing achievements in sales and marketing, but is most satisfied when he can translate that success to his team and others. Sharing his passion and time with multiple nonprofits he has also held various board positions in support of his community. Most recently, he finished his MBA at Cornell University and holds a BSc from Simon Fraser University. When not driving sales, he prefers to be at the helm of a boat, and as an avid sailor has raced around the world, completing multiple Pacific and Atlantic Ocean crossings.

Jason Flowerday MBA

Director

Jason Flowerday MBA
Director

Mr. Flowerday has two decades of experience in healthcare management and communications. Mr. Flowerday joined Knight Therapeutics Inc. in 2014 in the roll of Vice President Commercial Operations following the successful sale of his company, Orphan Canada, to Knight. In his role as founder and Chief Commercial Officer of Orphan Canada (formerly GARD Therapeutics), Mr. Flowerday funded and led the company through in-licensing and commercializing of its lead products which dealt with genetic and rare diseases. Prior to founding Orphan Canada, Mr. Flowerday established RxMedia Healthcare Communications, leading the company through a period of sustained growth and expansion. Mr. Flowerday holds a Bachelor of Science (Honours) from the University of Toronto and a Masters of Business Administration from Queen’s University.  

Rodoula Plakogiannis PharmD • BCPS • CLS • FNLA

Director

Rodoula Plakogiannis PharmD • BCPS • CLS • FNLA
Director

Dr. Plakogiannis is an Associate Professor of Pharmacy Practice at the Arnold & Marie Schwartz College of Pharmacy since 2002; and Adjunct Associate Professor at NYU Langone Medical Center since 2011. She received both her Bachelor of Science in Pharmacy and traditional Doctor of Pharmacy degrees from the Arnold & Marie Schwartz College of Pharmacy & Health Sciences. Dr. Plakogiannis completed an ASHP-accredited specialized pharmacy residency in primary care at the Bay Pines Veterans Medical Center in Tampa, Fl. She is a Board Certified Pharmacotherapy Specialist, a Diplomat and Fellow of the Accreditation Council for Clinical Lipidology, and a Board Certified Clinical Lipid Specialist. She serves as one of the Board of Directors for the Northeastern Lipid Association and on the Accreditation Council for Clinical Lipidology 's Board of Governors. She also serves as the Adverse Drug Reactions Section Editor for the Journal of Pharmacy Practice. Dr. Plakogiannis has presented on a national level in addition to local seminars,and has been invited to serve as a consultant at the Aegerion and Amarin Lipid Pharmaceuticals Advisory Board meetings, among others.

Our Partners

news Releases

Aug 10, 2018
Aequus Closes Balance of $775,000 Equity Financing
Aug 09, 2018
Aequus Announces Fully-subscribed $775,000 Equity Financing
Jul 31, 2018
Aequus Announces Closing of $800,000 Equity Financing
Jul 24, 2018
Issuance of Stock Options
Jul 23, 2018
Aequus Announces Proposed $800,000 Equity Financing To Next Edge Biotech Plus Fund
Jul 19, 2018
Aequus Announces Expansion of Market Opportunity for its Long Acting Anti-Nausea Transdermal Patch
Jul 16, 2018
Aequus Extends and Enhances Commercial Agreement to Promote Vistitan in Canada
Jul 13, 2018
Aequus Announces New Independent Director to its Board
Jun 20, 2018
Aequus and Corium Join Forces to Advance Anti-Nausea Transdermal Patch
Jun 18, 2018
Aequus Announces First Canadian Cataract Procedures Using Zepto Capsulotomy System
May 31, 2018
Aequus Provides First Quarter 2018 Financial and Corporate Highlights
May 16, 2018
Aequus Announces Official Launch of Zepto Capsulotomy System in Canada to be June 1, 2018
May 03, 2018
Aequus Receives Positive FDA Regulatory Guidance for Anti-Nausea Patch
Apr 27, 2018
Aequus Provides Fourth Quarter and Fiscal 2017 Financial Highlights, Third Consecutive Quarter of Revenue Growth
Apr 26, 2018
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 2, 2018
Apr 17, 2018
Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program
Apr 12, 2018
Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio
Mar 19, 2018
Aequus Expands Market in Quebec for Tacrolimus IR
Mar 07, 2018
FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch
Mar 05, 2018
Aequus and EHave enter into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
Jan 31, 2018
Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch
Jan 25, 2018
Aequus Announces Change to Proposed $300,000 Equity Financing
Jan 11, 2018
CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders
Jan 11, 2018
Aequus Announces Proposed $300,000 Equity Financing
Dec 08, 2017
Aequus announces the issuance of stock options
Nov 29, 2017
Aequus Provides Third Quarter 2017 Operational Highlights
Nov 16, 2017
Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole
Oct 10, 2017
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole
Sep 07, 2017
Aequus Announces Positive Results for Proof of Concept Clinical Trial of Anti-Nausea Patch
Aug 29, 2017
Aequus Provides Second Quarter 2017 Operational Highlights
Aug 24, 2017
Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole
Aug 17, 2017
Aequus Receives Approval for Short Form Base Shelf Prospectus to Raise up to C$20,000,000
Aug 01, 2017
Aequus and Scientus Agree to Terms for a Medical Cannabis Commercial Supply and Product Development Collaboration
Jul 05, 2017
Aequus Receives Approval from Health Canada to Initiate Proof of Concept Clinical Trial of Anti-Nausea Patch
Jun 15, 2017
Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch
Jun 13, 2017
Santen and Aequus Enter Into a Commercial Collaboration in Canada
Jun 12, 2017
Aequus Approves Advance Notice Policy
Jun 01, 2017
Aequus Pharmaceuticals and CDRD Announce Research Collaboration to Improve Cannabinoid-Based Therapeutics
May 30, 2017
Aequus Provides First Quarter 2017 Financial Highlights
May 15, 2017
Aequus Validates Need for Improved Delivery Methods of Medical Cannabis
May 01, 2017
Aequus Provides Fourth Quarter and Fiscal 2016 Financial Highlights
Apr 05, 2017
Aequus Launches Medical Cannabis Physician Research in US and Canada
Apr 03, 2017
Aequus Announces Positive Results from Second Proof of Concept Study for Long-Acting Aripiprazole Transdermal Patch
Mar 13, 2017
Aequus Raises $5.2 Million Through Bought Deal Financing Including Full Exercise of the Over-Allotment Option
Mar 03, 2017
Aequus Announces Upsizing of Previously Announced Bought Deal of Units to $4.5 Million
Mar 02, 2017
Aequus Announces $3 Million Bought Deal Financing
Mar 02, 2017
Aequus Licenses Rights to Cannabinoid Transdermal Patch to Treat Neurological Disorders
Feb 14, 2017
Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch
Feb 01, 2017
Aequus Receives Non-Dilutive Funding from the Government of Canada to Support Aripiprazole Patch Development
Jan 09, 2017
Aequus Initiates Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch
Dec 01, 2016
Aequus Obtains Public Reimbursement for Vistitan in Two Additional Provinces: Alberta and Manitoba
Nov 30, 2016
Aequus Provides Q3 2016 Financial Highlights with Substantial Increase in Quarter over Quarter Revenues
Nov 17, 2016
Aequus Prepares for Proof of Concept Clinical Study for Transdermal Anti-Nausea Diclegis Program
Oct 17, 2016
Aequus Advances Clinical Development of Transdermal Aripiprazole Patch
Oct 03, 2016
Aequus Partners with Camargo to Support US Regulatory Strategy for Development Programs
Sep 29, 2016
Aequus Obtains Ontario Provincial Listing for Vistitan™
Sep 13, 2016
Aequus Closes Financing for Gross Proceeds of C$2,743,920
Sep 06, 2016
Aequus Pharmaceuticals Inc. Announces $2.0 to $4.0 Million Best Efforts Financing
Aug 30, 2016
Aequus Provides Corporate Update on Commercial and Development Programs
Aug 05, 2016
Aequus Announces Advancement of Anti-Nausea Transdermal Extended-Release Patent Application
Jul 29, 2016
Aequus Announces Advancement of Clobazam Transdermal Patent Application
Jul 22, 2016
Aequus appoints Ann Fehr as Chief Financial Officer
May 02, 2016
Aequus Announces Stock Option Grant
Apr 28, 2016
Aequus Pharmaceuticals Initiates Promotional Efforts for VISTITAN™ in Canada
Apr 26, 2016
Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference
Feb 26, 2016
Aequus Awarded Growth Stage Life Sciences Company of the Year
Feb 16, 2016
Aequus Licenses Canadian Commercialization Rights to Trokendi XR® and Oxtellar XR® from Supernus
Feb 04, 2016
Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch
Jan 18, 2016
Aequus Pharmaceuticals to Present at Noble Capital Markets’ Investor Conference
Jan 12, 2016
Aequus Closes Previously Announced Equity Financings
Jan 07, 2016
Aequus Announces Proposed Equity Financings of Up to C$2,750,000
Dec 14, 2015
Aequus Announces Completion of Dosing in Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
Dec 02, 2015
Aequus Pharmaceuticals Initiates Promotional Efforts for Transplant Product in Canada
Nov 16, 2015
Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch
Oct 30, 2015
Aequus Closes Financing for Gross Proceeds of C$1,237,500
Oct 21, 2015
Aequus Announces Terms of Public Offering of Common Shares
Oct 05, 2015
Aequus Announces Stock Option Grant
Oct 05, 2015
Aequus Announces Proposed Offering of Common Shares
Sep 30, 2015
Aequus Announces a Binding Term Sheet for the Marketing and Promotion of Transplant Products in Canadian Market
Aug 27, 2015
Aequus Pharmaceuticals Announces Trading on OTCQB
Jul 28, 2015
Aequus Pharmaceuticals Announces the Completion of the Acquisition of TeOra Health
Jul 23, 2015
Positive Preclinical Results and Patent Allowed for Aequus’ Once-Weekly Transdermal Aripiprazole
Jul 13, 2015
Aequus Pharmaceuticals Announces It Has Entered into a Definitive Agreement to Acquire TeOra Health and Intends to Promote Its First Commercial Product in Canada in 2015
May 28, 2015
Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole
May 26, 2015
Aequus Retains Investor Relations Representative
Apr 28, 2015
Aequus and Corium Enter into Product Development Collaboration Focused on CNS
Mar 16, 2015
Aequus Pharmaceuticals Lists on the TSX Venture Exchange and Appoints New Director
Mar 11, 2015
Aequus Pharmaceuticals Receives Conditional Approval To Commence Trading On TSX-V Exchange
Feb 20, 2015
Aequus Pharmaceuticals Becomes Reporting Issuer
Nov 20, 2014
Aequus Pharmaceuticals Closes $4.2 Million Private Placement Financing
May 27, 2014
Aequus Pharmaceuticals Announces Development Agreement for Transdermal Aripiprazole with Corium International
Sep 25, 2013
Aequus Pharmaceuticals Inc. closes on C$1.2 Million in equity financings, and in-licenses global rights to intellectual property enabling the transdermal delivery of aripiprazole
MORE TWEETS